SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
StockNews.AI · 2 hours
AI Summary
SeaStar Medical announced dedicated ICD-10-PCS codes for QUELIMMUNE SCD-PED, enabling inpatient billing for AKI requiring RRT. Codes take effect October 1, 2026 and could unlock rapid adoption in a $4.5B adult AKI market, about 50x the pediatric market. The NEUTRALIZE-AKI trial in 339 adults will be a key readout for potential expansion into ICU AKI indications.
Sentiment Rationale
Regulatory coding codes and a large TAM for adult AKI create tangible near-term upside potential; adoption hinges on trial outcomes but the reimbursement framework materially lowers deployment barriers in ICUs.
Trading Thesis
Bullish; reimbursement codes unlock ICU AKI adoption, with upside tied to NEUTRALIZE-AKI results within 12–24 months.
Market-Moving
- Oct 1, 2026 coding effective, enabling hospital billing for QUELIMMUNE in ICU settings.
- Adult AKI TAM ~ $4.5B; potential to exceed pediatric market implications.
- NEUTRALIZE-AKI pivotal trial results pending; readout could meaningfully shift adoption.
- Breakthrough Device Designation supports faster potential commercialization and reimbursement dynamics.
Key Facts
- CMS assigns ICD-10-PCS codes for QUELIMMUNE. Codes take effect Oct 1, 2026.
- Adult AKI market potential around $4.5B; ~50x pediatric.
- NEUTRALIZE-AKI trial: 339 adults; primary endpoint 90-day mortality or dialysis.
- QUELIMMUNE (SCD-PED) approved Feb 2024; pediatric ICU use.
- Codes to ease hospital billing and broaden adoption.
Companies Mentioned
- SeaStar Medical Holding Corporation (ICU): Catalyst-driven expansion potential; ICD-10-PCS codes could accelerate hospital uptake and AKI revenue.
- QUELIMMUNE (N/A): SCD-PED therapy; approved for pediatric AKI under HDE; basis for adult AKI expansion.
- NEUTRALIZE-AKI Trial (N/A): Pivotal adult AKI study; 339 patients; readouts influence expansion into ICU.
Corporate Developments
Category: Corporate Developments; fits as a regulatory/market-access advancement with direct ICU implications and near-term revenue impact.